Flexible Lifestyles for Youth (FL3X) behavioural intervention for at-risk adolescents with Type 1 diabetes: a randomized pilot and feasibility trial by Mayer-Davis, E. J. et al.
Flexible Lifestyles for Youth (FL3X) behavioural intervention for 
at-risk adolescents with Type 1 diabetes: a randomized pilot and 
feasibility trial
E. J. Mayer-Davis1,*, M. Seid2,*, J. Crandell4, L. Dolan6, W. H. Lagarde8, L. Letourneau3, D. 
M. Maahs7, S. Marcovina, PhD, DSc9, J. Nachreiner3, D. Standiford6, J. Thomas3, and T. 
Wysocki5
1Department of Nutrition and Department of Medicine, University of North Carolina Chapel Hill, 
Chapel Hill, NC
2Division of Pulmonary Medicine and Anderson Center for Health Systems Excellence, Cincinnati 
Children’s Hospital Medical Center, Cincinnati, OH
3Department of Nutrition, University of North Carolina Chapel Hill, Chapel Hill, NC
4School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, NC
5Department of Research, Nemours Children's Clinic, Jacksonville, FL
6Division of Pediatric Endocrinology, Cincinnati Children’s Hospital Medical Center, Cincinnati, 
OH
7Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO
8Children’s Endocrinology and Diabetes, WakeMed Children’s Hospital, Raleigh, NC, USA
9Northwest Lipid Metabolism and Diabetes Research Laboratories University of Washington 
Seattle, WA
Abstract
Aim—To determine the potential effect sizes for the Flexible Lifestyle for Youth (FL3X) 
behavioural intervention to improve glycaemic control (HbA1c) and quality of life for at-risk 
adolescents with Type 1 diabetes.
Methods—Participants [n=61; age 12–16 years, HbA1c 64–119 mmol/mol (8–13%)] were 
randomized to FL3X (minimum three sessions) or usual care. Effect sizes (Cohen’s d), comparing 
the mean difference between the groups, were calculated.
Results—Study retention (95%), attendance at intervention sessions (87% attended all three 
sessions) and acceptability were high (100% of the adolescents and 91% of parents would 
recommend the programme to others). Overall, 41% of participants in the intervention group and 
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24% of participants in the control group were ‘responders’ [HbA1c decreased by > 6 mmol/mol 
(0.5%); d=0.37]. HbA1c levels decreased (d= −0.18), diabetes-specific quality of life increased 
(d=0.29), but generic quality of life decreased (d= −0.23) in the intervention compared with the 
control group.
Conclusions—The FL3X programme merits further study for improving HbA1c and diabetes-
specific quality of life in adolescents with Type 1 diabetes.
Introduction
Poor and minority adolescents with Type 1 diabetes commonly have poor glycaemic control 
[1]. Diabetes self-management is key to long-term health, but can be challenging [2–4]. 
Efficacious interventions to improve HbA1c levels, especially in at-risk young people, are 
urgently needed.
Motivational interviewing has proven to be efficacious in improving HbA1c levels [5] and 
problem-solving interventions can improve self-efficacy [6], frequency of blood glucose 
testing [7], anxiety, stress and coping [8], and quality of life [9]. An intervention combining 
motivational interviewing and problem-solving could prove valuable.
Multicomponent interventions have also been shown to be efficacious. For example, 
diabetes-specific behavioural family systems therapy [10] improves HbA1c levels and 
multisystemic therapy improves adherence in adolescents with chronically poor glycaemic 
control [11], but these interventions are intense, which raises issues of sustainability. Two 
multicomponent interventions suggest a way forward. Nansel et al. [12–13] reported 
improvements in HbA1c as a result of a six-session behavioural self-regulation intervention 
implemented by a diabetes ‘personal trainer’, who used motivational interviewing 
techniques. Seid et al. [14] reported an adherence intervention that combined motivational 
interviewing with problem-solving skills training, and yielded important clinical benefits 
among low-income African-American adolescents with asthma.
The Flexible Lifestyles for Youth intervention (FL3X) combines motivational interviewing 
and problem-solving skills training with elements of behavioural family systems therapy and 
a flexible 'toolkit' of diabetes and communication technology. We sought to test the 
acceptability, feasibility and potential effect sizes for FL3X in at-risk adolescents with Type 
1 diabetes.
Methods
Setting
The present pilot and feasibility study was performed as a three-site randomized clinical 
trial, comparing usual care (control) with the FL3X (intervention). The project was managed 
from the University of North Carolina, Chapel Hill. The three collaborating clinical sites 
included: 1) the Cincinnati Children’s Hospital Medical Center (Cincinnati, OH); 2) the 
Barbara Davis Center for Childhood Diabetes (Aurora, CO); and 3) the WakeMed 
Children’s Hospital (Raleigh, NC).
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The study was approved by the institutional review boards at all participating institutions 
and was registered with clinicaltrials.gov (NCT01286350).
Participants
Adolescents aged 12–16 years with a diagnosis of Type 1 diabetes for ≥1 year, literacy in 
English, HbA1c 64–119 mmol/mol (8–13%) and at least one primary caregiver were 
included. Adolescents were excluded if pregnant or if they had concurrent conditions that 
precluded participation, such as cancer or bipolar disorder.
Participants were recruited between May 2011 and August 2011. The final follow-up visit 
was completed in December 2011. Potential participants were identified via medical records 
and recruited via their clinicians and by mail and telephone calls. Participants received $40 
for each measurement visit and were provided with a basic telephone (i.e. not a smartphone) 
with unlimited talk and text messaging for the duration of the study.
Study groups and randomization
Participants were randomized, within each clinical site, electronically via a predetermined 
allocation embedded within the study website to the FL3X intervention or usual care 
(control) groups.
The FL3X programme is framed through motivational interviewing [14–15], and uses the 
Bright IDEAS problem-solving skills training [14] and behavioural family systems therapy 
[10]. Additionally, FL3X makes use of a ‘toolbox’ of existing off-the-shelf applications, 
devices and diabetes-related educational materials. The FL3X intervention included three in-
person and two optional sessions over a 3-month period. Sessions lasted 40–60 min and 
were supplemented with short additional contacts as needed. Participants were given the 
option of using their telephone to create reminders about diabetes management (e.g. insulin 
dosing and testing reminders) and/or motivational boosters (‘messages from you to 
yourself’).
Participants in the control group continued with their usual diabetes care.
Intervention training
The FL3X coaches were four experienced paediatric diabetes clinicians/educators. They 
participated in a 2-day motivational interviewing training and a 2-day recruitment and 
intervention workshop. Continuing training and supervision calls for coaches were held 
weekly.
Outcome measures
Baseline and 4-month end-of-study measures were collected in person. The primary 
outcome was change in HbA1c level, assessed as the percentage of participants with a 
reduction in HbA1c of > 6 mmol/mol (0.5%) between baseline and the end of study 
('responders'), and as change in HbA1c as a continuous variable. Dual reporting of HbA1c 
values was achieved using a HbA1c conversion table [17].
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Secondary outcomes were disease-specific health-related quality of life, measured using the 
Pediatric Diabetes Quality of Life (PDQ) assessment [18] and generic health-related quality 
of life, measured using The PedsQL™ 4.0 Generic Core Scales [16].
Fidelity
Intervention sessions were audio-recorded and reviewed by an external MINT-certified 
coder, who scored selected sessions using the Motivational Interviewing Treatment Integrity 
3.0 system [24]. In addition, trained graduate research assistants used a behavioural checklist 
to reflect the extent to which the intervention providers followed the content guidelines for 
each session.
Analysis
The goals of the analysis were to describe feasibility, acceptability, fidelity and potential 
effect sizes by comparing the intervention and control groups. Potential effect sizes were 
assessed using Cohen’s d, the average change in the intervention minus the average change 
in the control group, divided by the (pooled) standard deviation of change. Effect sizes were 
interpreted as small (d = 0.2), medium (d = 0.5) or large (d = 0.8) [19]. Although, by design, 
the study was not adequately powered to reject the null hypothesis, we also performed 
inferential statistics (t-tests for continuous outcomes and chi-squared tests for dichotomous 
outcomes).
Results
The basic demographic and clinical characteristics did not differ by randomization 
assignment. The mean (SD) age and diabetes duration of the participants were 13.9 (1.4) 
years and 7.4 (3.5) years, respectively. Baseline glycaemic control was poor [mean (SD) 
HbA1c 83 (16) mmol/mol or 9.7 (1.5)%]. In all, 17% of the participants had low socio-
economic status (the highest attained parental education level was high school or lower), and 
22% of participants received government-sponsored health insurance.
Figure 1 shows the flow of participants. The potential eligible study population consisted of 
384 adolescents. After making contact with 130, we stopped because our recruitment goals 
had been attained. Of those contacted, three adolescents were deemed ineligible or 
withdrew, 58 declined to participate and eight did not present for the baseline appointment, 
resulting in a total of 61 participants available for randomization (47% of those contacted).
Retention was excellent, with 95% attendance at the end-of-study measurements and 97, 90 
and 90% attendance for Sessions 1, 2, and 3, respectively (87% of participants attended all 
three sessions). Intervention acceptability was high: 100% of the adolescents and 91% of 
their parents indicated they would recommend the programme to others.
The Motivational Interviewing Treatment Integrity 3.0 system scores (1–5, with 5 being 
best) averaged 4.4 (range, 3.7–4.7) for all four intervention coaches, showing high 
adherence to motivational interviewing strategies. Fidelity to the intervention script for 
Session 1 by all four coaches was 95%; however, over all three sessions, two coaches 
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emerged as having 'high' fidelity (averaging 89.5% fidelity to script across all three 
sessions), while the other two coaches averaged a fidelity score of 51.5%.
Table 1 shows the effect sizes and inferential statistics for the outcome variables, comparing 
the intervention group (n= 29) with the control group (n=29). We found a modest effect size 
for the primary outcome: 41% of intervention participants and 24% of control participants 
were responders (d=0.37; P = nonsignificant). HbA1c levels decreased by 2 mmol/mol 
(0.2%) for the intervention group and remained the same for the control group (d = −0.18; P 
= nonsignificant). In the subgroup of participants in the intervention group whose coaches 
administered the FL3X intervention with high fidelity, medium effects were found: 57% 
were responders (d= 0.73; P = 0.03 vs control group) and HbA1c decreased by 6 mmol/mol 
(0.5%; d= −0.58; P = 0.09 vs control group).
For diabetes-related quality of life as measured by the PDQ, the effect size was modest 
(d=0.29; P = nonsignificant). For generic health-related quality of life, scores were slightly 
lower in the intervention group (d = −0.23; P = nonsignificant). Although scores increased 
numerically in the control group, this was not considered clinically relevant and was not 
statistically significant.
Discussion
The present pilot test of the FL3X intervention shows that the approach used is worthy of 
further study, including longer follow-up and a larger sample size. Nevertheless, the study 
has some limitations. By design, the pilot was not powered to detect a statistically 
significant intervention effect. Two of the four coaches were observed to have maintained 
moderate, as opposed to high, fidelity to the intervention. Unfortunately, our fidelity ratings 
were not completed in a timely enough manner to be used to deliver specific behavioural 
feedback in supervision sessions, which limited our ability to provide specific feedback to 
the coaches. This highlights the importance of fidelity for intervention delivery, and 
accordingly, we have developed a much more specific manual of procedures for use in 
future. Finally, the effect size of HbA1c was small. Other studies [6–9, 12–13] suggest it 
takes a longer time period and a higher dose to achieve larger effects. This will need to be 
addressed in a fully powered, longer clinical trial.
Conclusions
The FL3X intervention shows promise as a potentially efficacious intervention for improved 
diabetes self-management in adolescents with Type 1 diabetes, including those at high risk 
of poor metabolic status related to socio-demographic status.
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What's new?
• Flexible Lifestyles for Youth (FL3X), is a new behavioural intervention that 
combines motivational interviewing, problem-solving skills, family 
communication and teamwork.
• The FL3X programme could improve metabolic status and quality of life for 
adolescents with Type 1 diabetes.
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FIGURE 1. 
Flexible Lifestyles for Youth (FL3X) pilot and feasibility study: CONSORT flow diagram.
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